Smith & Nephew plc (SN.L)
| Previous close | 1,335.50 |
| Open | 1,331.00 |
| Bid | 1,332.00 x 0 |
| Ask | 1,332.50 x 0 |
| Day's range | 1,325.00 - 1,340.00 |
| 52-week range | 1,294.00 - 1,681.50 |
| Volume | 4,775,930 |
| Avg. volume | 2,130,602 |
| Market cap | 11.716B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 29.03 |
| EPS (TTM) | 45.90 |
| Earnings date | 29 Jul 2021 |
| Forward dividend & yield | 0.27 (2.02%) |
| Ex-dividend date | 30 Sept 2021 |
| 1y target est | 16.78 |
- Simply Wall St.
Estimating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)
How far off is Smith & Nephew plc ( LON:SN. ) from its intrinsic value? Using the most recent financial data, we'll...
- Motley Fool
Will a Powerful Acquisition Make This Early 2021 IPO a Buy?
Bioventus (NASDAQ: BVS) is a company that specializes in developing innovations in biologics and clinical therapies for active healing. In February of this year, Bioventus opened its doors of ownership to the public by way of an IPO of 8 million shares. Leading up to the spin-off, Smith & Nephew was experiencing strong growth from the biologics and clinical therapies unit, with annual revenue growing from $52 million in 2004 to $223 million in 2010 for that unit alone.
- The Telegraph
Questor: it’s not immune from inflation but Smith & Nephew is a quality business. Keep buying
One common refrain from companies during the second-quarter reporting season has been how their input costs are rising, be they commodity, raw material, shipping or even wage costs. Even the medical equipment specialist Smith & Nephew is not proving immune and this may explain why the shares slid quite so far after last month’s interims.
